Comparing early and late medication for heart attack recovery
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
This study tests whether giving heart medications right away or waiting a bit helps people recover better after a heart attack.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Vastra Gotaland Region Government |
| Locations | 1 site (Gothenburg) |
| Trial ID | NCT06562582 on ClinicalTrials.gov |
What this trial studies
This trial investigates the effects of immediate versus delayed administration of beta blockers, ACE inhibitors, and SGLT2 inhibitors on heart function and biomarkers in patients experiencing ST-elevation myocardial infarction (STEMI). It aims to understand how these treatments influence early left ventricular remodeling after a heart attack. The study will enroll patients who undergo primary percutaneous coronary intervention (PCI) within six hours of symptom onset and will measure outcomes such as global longitudinal strain at day 7 post-PCI.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who have experienced STEMI and are undergoing primary PCI within six hours of symptom onset.
Not a fit: Patients with severe heart failure, chronic kidney disease, or those currently on specific heart medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve recovery outcomes for patients who have suffered a heart attack by optimizing medication timing.
How similar studies have performed: Previous studies have shown varying success with similar approaches, but this specific timing comparison is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms) 2. Informed consent Exclusion Criteria: 1. Killip class ≥ 3 2. Chronic kidney disease with GFR \< 25 ml/min/1.73 m2 3. Pre-existing non-reversible cardiac dysfunction or heart failure 4. Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor 5. Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician 6. Life expectancy less than one year 7. Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception
Where this trial is running
Gothenburg
- Sahlgrenska University Hospital — Gothenburg, Sweden (Recruiting)
Study contacts
- Study coordinator: Björn Redfors, Professor
- Email: bjoern.redfors@wlab.gu.se
- Phone: +46 31342100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.